A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
Trial registration ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-11-01
|
| Series: | Translational Neurodegeneration |
| Online Access: | https://doi.org/10.1186/s40035-023-00387-5 |
| _version_ | 1797556961633370112 |
|---|---|
| author | Alireza Faridar Abdulmunaim M. Eid Aaron D. Thome Weihua Zhao David R. Beers Maria B. Pascual Mohammad O. Nakawah Gustavo C. Roman Charles S. Davis Michael Grundman Joseph C. Masdeu Stanley H. Appel |
| author_facet | Alireza Faridar Abdulmunaim M. Eid Aaron D. Thome Weihua Zhao David R. Beers Maria B. Pascual Mohammad O. Nakawah Gustavo C. Roman Charles S. Davis Michael Grundman Joseph C. Masdeu Stanley H. Appel |
| author_sort | Alireza Faridar |
| collection | DOAJ |
| description | Trial registration ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153 |
| first_indexed | 2024-03-10T17:10:36Z |
| format | Article |
| id | doaj.art-e8a0ebe6290e4359b7e72393eaf523ef |
| institution | Directory Open Access Journal |
| issn | 2047-9158 |
| language | English |
| last_indexed | 2024-03-10T17:10:36Z |
| publishDate | 2023-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Translational Neurodegeneration |
| spelling | doaj.art-e8a0ebe6290e4359b7e72393eaf523ef2023-11-20T10:42:22ZengBMCTranslational Neurodegeneration2047-91582023-11-011211410.1186/s40035-023-00387-5A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s diseaseAlireza Faridar0Abdulmunaim M. Eid1Aaron D. Thome2Weihua Zhao3David R. Beers4Maria B. Pascual5Mohammad O. Nakawah6Gustavo C. Roman7Charles S. Davis8Michael Grundman9Joseph C. Masdeu10Stanley H. Appel11Stanley H. Appel Department of Neurology, Houston Methodist Research InstituteStanley H. Appel Department of Neurology, Houston Methodist Research InstituteStanley H. Appel Department of Neurology, Houston Methodist Research InstituteStanley H. Appel Department of Neurology, Houston Methodist Research InstituteStanley H. Appel Department of Neurology, Houston Methodist Research InstituteStanley H. Appel Department of Neurology, Houston Methodist Research InstituteStanley H. Appel Department of Neurology, Houston Methodist Research InstituteStanley H. Appel Department of Neurology, Houston Methodist Research InstituteCSD Biostatistics, Inc.Global R&D Partners, LLCStanley H. Appel Department of Neurology, Houston Methodist Research InstituteStanley H. Appel Department of Neurology, Houston Methodist Research InstituteTrial registration ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153https://doi.org/10.1186/s40035-023-00387-5 |
| spellingShingle | Alireza Faridar Abdulmunaim M. Eid Aaron D. Thome Weihua Zhao David R. Beers Maria B. Pascual Mohammad O. Nakawah Gustavo C. Roman Charles S. Davis Michael Grundman Joseph C. Masdeu Stanley H. Appel A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease Translational Neurodegeneration |
| title | A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease |
| title_full | A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease |
| title_fullStr | A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease |
| title_full_unstemmed | A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease |
| title_short | A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease |
| title_sort | phase 1 open label pilot study of low dose interleukine 2 immunotherapy in patients with alzheimer s disease |
| url | https://doi.org/10.1186/s40035-023-00387-5 |
| work_keys_str_mv | AT alirezafaridar aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT abdulmunaimmeid aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT aarondthome aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT weihuazhao aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT davidrbeers aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT mariabpascual aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT mohammadonakawah aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT gustavocroman aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT charlessdavis aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT michaelgrundman aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT josephcmasdeu aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT stanleyhappel aphase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT alirezafaridar phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT abdulmunaimmeid phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT aarondthome phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT weihuazhao phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT davidrbeers phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT mariabpascual phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT mohammadonakawah phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT gustavocroman phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT charlessdavis phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT michaelgrundman phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT josephcmasdeu phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease AT stanleyhappel phase1openlabelpilotstudyoflowdoseinterleukine2immunotherapyinpatientswithalzheimersdisease |